LENZ Therapeutics' VIZZ earns FDA approval as the first aceclidine-based eye drop to treat presbyopia, with U.S. launch expected in Q4 2025.

Alcon launched Tryptyr, a treatment for the signs and symptoms of dry eye disease, in the U.S. Tryptyr (acoltremon ophthalmic solution 0.003%) is a TRPM8 receptor agonist that showed a “statistically ...

In this Healio Video Perspective from the American Society of Retina Specialists annual meeting, Sunir J. Garg, MD, FACS, ...

LENZ Therapeutics ( (LENZ) ) has shared an announcement. On July 31, 2025, LENZ Therapeutics announced the FDA approval of VIZZ, an aceclidine-based eye drop for treating presbyopia in adults, ...

Vizz (Lenz Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution ...